FDA Accepts Biodel’s New Drug Application for Review

Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel’s proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs.
The new drug has been tested in more than 875 patients who participated in Phase 1, 2 and 3 clinical trials of the drug in the United States, Germany and India.

ASweetLife Team

FDA Accepts Sanofi’s NDA for New Basal Insulin, Toujeo
The U.S. Food and Drug Administration (FDA) has accepted for review Sanofi’s New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The…
FDA Grants Tentative Approval to Lilly’s New Insulin…
The U.S. FDA has granted tentative approval for Basaglar (insulin glargine injection). With a tentative approval, the FDA has determined that Basaglar meets all of the regulatory requirements for approval, but it…
FDA Approves Toujeo, Sanofi’s New Long Acting Insulin
The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type…
FDA Approves Basaglar, Lilly-Boehringer Ingelheim New Long
The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes alliance. Basaglar is a long-acting human insulin analog which is used to improve glycemic control in adult…
FDA Approves Basaglar, Lilly-Boehringer Ingelheim New Long
The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes alliance. Basaglar is a long-acting human insulin analog which is used to improve glycemic control in adult…